Ocugen Reports Positive Phase 2 Data for OCU410 Therapy

Ocugen ( (OCGN) ) just unveiled an announcement.

On March 24, 2026, Ocugen reported positive 12‑month topline data from its Phase 2 ArMaDa trial of OCU410, a one-time AAV5-based modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration. The study showed a 31% reduction in lesion growth at the planned Phase 3 dose versus control, preservation of photoreceptor structure, and a clean safety profile without serious OCU410-related adverse events, positioning the program for a Phase 3 registrational trial in the third quarter of 2026 and potentially strengthening Ocugen’s standing in the emerging GA treatment landscape.

The most recent analyst rating on (OCGN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Ocugen stock, see the OCGN Stock Forecast page.

Spark’s Take on OCGN Stock

According to Spark, TipRanks’ AI Analyst, OCGN is a Neutral.

The score is held back primarily by weak financial performance (ongoing losses/cash burn and negative equity). Offsetting this are constructive technical momentum and a generally positive earnings narrative around clinical progress and defined regulatory timelines, while valuation provides limited support and corporate events are mixed (runway extension vs. legal overhang).

To see Spark’s full report on OCGN stock, click here.

More about Ocugen

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies to address major blindness diseases. Leveraging a modifier gene therapy platform and a gene-agnostic approach, the company targets large patient populations with significant unmet medical need in retinal and other ophthalmic disorders.

Average Trading Volume: 7,513,991

Technical Sentiment Signal: Buy

Current Market Cap: $688.6M

For detailed information about OCGN stock, go to TipRanks’ Stock Analysis page.